top of page

"Medical Affairs Consulting, Inspiring Impactful Change in Health Equity"

  • Medical affairs outsourcing companies are essential for non-promotional expert scientific and medical information to healthcare professionals, participating in pre- and post launch activities, identifying insights from key opinion leaders, engaging with patient advocacy groups, advisory boards, etc.

  • Field based medical science liaisons (MSLs) attend conferences, provide training, develop materials, and develop strategy. 

Adalynn E. Harris, PhD, MPH, MHA
Founder and President

• HBCU Graduate: Morehouse School of Medicine; NC A&T State University

• Other Graduate Degrees: UNC-Chapel Hill; George Washington University

• Post-Doctoral Fellowship: Fellowship In Research and Science Teaching (FIRST)

• Medical Affairs Experience: 15+ years in pharmaceutical industry

• Career Experience: Clinical Trial/Scientific Support; Health Disparities; Strategy Design and Implementation; Advisory Board Facilitation

President in Red Jacket 2023.jpg
Blue Background

COMPANY VISION

•  Equity Bridge ConsultingSM provides scientific support for all the for inclusion of persons who have historically been un- or under-represented in research/clinical trials arena. ​

 

This is accomplished via:

•  Medical affairs-based activities including (1) strategic interactions; (2) diversity education (i.e. the need for diverse inclusion in basic research, clinical trial and public health areas) to the pharmaceutical, academic and community institution; (3)HEOR assistance for subsidiaries and sites (academic and community) specifically regarding minority issues; and (4) Assistance with Clinical development activities.

 

​•  Global outreach to include sub-Saharan Africa and persons from the African diaspora. 

Abstract Linear Background

Pillars:

Abstract Linear Background

1

Industry

•Provide drivers of innovation with medical affairs outsourcing

•Filling gaps in medical affairs capabilities 

•Assistance with Clinical Trial Accrual for minority groups

2

Marginalized Communities and Patient Advocacy Groups

•Scientific Updates on Drugs/Diagnostics

•Discussions on Clinical Trial Data

•Relaying Drug and Diagnostics Development

•Education regarding Adverse Events/ Safety

3

Clinical Research Workforce

Diversity in Workforce Development Strategy

•Minority physicians and scientists

•Diversification built in all levels of clinical trials

•Special Attention to HBCUs/MSIs

bottom of page